OXNARD, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery company, today reported the
company’s Q1 2018 accomplishments. The company strengthened its leadership team with biopharmaceutical expertise, secured
additional financing, and boosted nutraceutical product distribution, while advancing towards the launch of its first
pharmaceutical CUREfilm™ product.
“We see solid growth this quarter that offers a strong jumping off point for the year ahead,” said Rob Davidson, CEO CURE
Pharmaceutical. “We are already seeing benefits from the additional operational and manufacturing talent that has streamlined
manufacturing to support growth in production. Each step is vital to our company’s growth to make medications easier to take, more
efficient, and with fewer side effects.”
In the first quarter of 2018, CURE Pharmaceutical has reported developments in the following key areas:
- Financing: Dr. Gene Salkind was named to CURE Pharmaceutical’s Advisory Board and invested $1 million in the
company. Additionally, Alexander Capital raised a $1 million bridge financing transaction for working capital to expand
production capabilities and accelerate product development.
-
Three Strategic Hires: The company bolstered its leadership team with the addition of Jessica Rousset as Chief Operating Officer,
Dr. Vered Gigi as its VP of
Business Development and Strategy, and former Amgen executive, Steven Ruhl as the VP of Manufacturing.
- Nutraceutical Sleep Demand Increase: The company grew product demand this quarter, including two new
purchase orders worth more than $500,000 in the nutraceutical sleep category. Due to leadership additions and improvements in
manufacturing this quarter, the company has increased its shipments by more than 300 percent over the average quarterly
shipments.
-
Advanced ED CUREfilm product development: The company has advanced its erectile dysfunction (ED) CUREfilm
product through manufacturing validation. CURE Pharmaceutical anticipates launching this product in Asia in Q2 2019. The global
ED drugs market is expected to reach USD 3.2 billion by 2022, according to a report by Grand
View Research Inc.
- Research: The first year of sponsored research at Israel’s Technion Institute of Technology has
concluded. Specific cannabis extracts and extraction methods that result in tumor cell death in vitro have been identified,
demonstrating that specific combinations of actives in the cannabis plant are responsible for the observed therapeutic effects,
and that those therapeutic effects are specific to the type of cancer.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety
and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP
manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™),
one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery
platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic
categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other
markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking Statement
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than
statements of fact, including those statements with respect to the Company’s business development, are forward-looking statements.
Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation
to publicly update or revise any forward-looking statements.
Contact: Ashley Ray
(310) 824-9000
aray@olmsteadwilliams.com
